Related Experiment Video

Updated: Aug 14, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K

Effectiveness and safety of four different beta-blockers in patients with chronic heart failure

Baoshan Liu1, Rui Zhang1, Aiyuan Zhang1

  • 1Department of Cardiology Qilu Hospital of Shandong University in Jinan, and Department of Cardiology Weifang People's Hospital Weifang Shandong P. R. China.

Medcomm
|January 11, 2023
PubMed

Insights

Bisoprolol demonstrated superior effectiveness in treating chronic heart failure compared to carvedilol. Other beta-blockers like metoprolol and nebivolol showed varying degrees of efficacy in this heart failure treatment study.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) is a complex condition requiring effective pharmacological management.
  • Beta-blockers are a cornerstone therapy for CHF, but comparative effectiveness data among specific agents can be limited.

Purpose of the Study:

  • To evaluate and compare the effectiveness and safety of four beta-blockers: bisoprolol, metoprolol, carvedilol, and nebivolol.
  • To establish a hierarchy of evidence for the efficacy of these agents in CHF treatment.

Main Methods:

  • Comparative effectiveness evaluation of bisoprolol, metoprolol (succinate and tartrate formulations), carvedilol, and nebivolol.
  • Assessment based on established evidence levels for treatment outcomes in chronic heart failure.

Main Results:

  • Bisoprolol showed a higher level of evidence for improving CHF prognosis compared to carvedilol.
  • Carvedilol demonstrated comparable effects to metoprolol succinate and nebivolol.
  • Carvedilol was more effective than metoprolol tartrate in CHF management.

Conclusions:

  • The evidence suggests a differential effectiveness among commonly used beta-blockers for chronic heart failure.
  • Bisoprolol appears to offer superior prognostic benefits over carvedilol.
  • Carvedilol, metoprolol succinate, and nebivolol represent a similar tier of effectiveness, superior to metoprolol tartrate.

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.3K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.5K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
412
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
922
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
795
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
549